Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
PDS0101
product7 mentionslast seen Nov 10, 2026
A novel investigational human papillomavirus targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers, part of the Versamune cancer vaccine platform.
Relationships 8
- PDS Biotechnology CorporationdevelopsPDS010199% confidence7 sources
- PDS0101applies toHPV16-positive head and neck cancer treatment99% confidence3 sources
- PDS0101applies toHPV16-positive cancer treatment99% confidence2 sources
- PDS0101depends onVersamune94% confidence1 source
- PDS0101depends onVersamune platform93% confidence1 source
- Versamune cancer vaccine platformcomposed ofPDS010190% confidence1 source
- PDS0101composed ofR-DOTAP88% confidence1 source
- VERSATILE-002 clinical trialcitesPDS010188% confidence1 source
Relationship
PDS Biotechnology CorporationdevelopsPDS0101
99% confidence7 supporting mentions
Either name opens that entity’s relationships.
Sources 7
- filingSEC EDGARNov 10, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PDS Biotechnology also owns the Versamune® cancer vaccine platform, including PDS0101, which has been evaluated in HPV16-positive cancers
- filingSEC EDGAROct 20, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PDS0101 (Versamune® HPV16 Cancer Vaccine)
- filingSEC EDGAROct 20, 2026PDS Biotechnology Corp 8-K: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PDS0101 toward potential partnerships
- filingSEC EDGAROct 6, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
including PDS0101, which has been evaluated in HPV16-positive cancers
- filingSEC EDGARSep 22, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PDS0101, its HPV16-targeted immunotherapy
- filingSEC EDGARSep 21, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Two clinically advanced assets built on proprietary platforms... PDS0101 (Versamune® HPV16 Cancer Vaccine)
- filingSEC EDGARSep 14, 2026PDS Biotechnology Corp 8-K: Item 1.02: Termination of a Material Definitive Agreement; Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PDS Biotechnology also owns the Versamune® cancer vaccine platform, including PDS0101